Biologic drugmaker Amgen’s Q4 profit jumps 30 per cent on higher sales, tax benefit, Onyx deal

THOUSAND OAKS, Calif. – Amgen Inc.’s fourth-quarter profit jumped 30 per cent due to higher sales for nearly all its drugs, an acquisition and a tax benefit.

The world’s biggest maker of biologic drugs says net income was $1.02 billion, or $1.33 per share, up from $788 million or per share a year earlier.

Excluding one-time items, Amgen says earnings amounted to $1.39 billion, or 1.82 per share. Analysts surveyed by FactSet were expecting $1.69 per share.

Revenue totalled $5.01 billion, up 13 per cent. Analysts expected $4.81 billion.

Sales were boosted by Amgen’s $9.7 billion purchase of Onyx Pharmaceuticals Inc. as part of Amgen’s strategy to become a major player in the market for pricey cancer drugs.

The company, based in Thousand Oaks, Calif., forecast 2014 adjusted earnings per share of $7.90 to $8.20.

News from © The Associated Press, . All rights reserved.
This material may not be published, broadcast, rewritten or redistributed.

The Associated Press

The Associated Press is an independent global news organization dedicated to factual reporting. Founded in 1846, AP today remains the most trusted source of fast, accurate, unbiased news in all formats and the essential provider of the technology and services vital to the news business. More than half the world’s population sees AP journalism every day.